Loncastuximab tesirine (Zynlonta, Swedish Orphan Biovitrum) is indicated for 'the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.'
The dosage schedule is available in the summary of product characteristics for loncastuximab tesirine.
The company has a commercial arrangement. This makes loncastuximab tesirine available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.